Ablation of the Ccr2 gene exacerbates polyarthritis in interleukin-1 receptor antagonist-deficient mice

Arthritis and Rheumatism

Volumn 63, Issue 1, 2011, Pages 96-106

  Fujii, Hiroshi ^a   Baba, Tomohisa ^a   Ishida, Yuko ^b   Kondo, Toshikazu ^b   Yamagishi, Masakazu ^a   Kawano, Mitsuhiro ^a   Mukaida, Naofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ADAM PROTEIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CELL INFILTRATION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ARTHRITIS; BODY WEIGHT; BONE DENSITY; CELL COUNT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; OSTEOCLASTS; RECEPTORS, CCR2; STATISTICS, NONPARAMETRIC;

EID: 78650762559     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30106     Document Type: Article

References (50)

1. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
2. Szekanecz Z, Koch AE,. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-95.
3. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 217-25.
4. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
5. Mukaida N,. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000; 72: 391-8.
6. Koch AE,. Chemokines and their receptors in rheumatoid arthritis: future targets? [review]. Arthritis Rheum 2005; 52: 710-21.
7. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I,. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997; 186: 131-7.
8. Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM, et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 2008; 180: 3447-56.
9. Kim MS, Day CJ, Morrison NA,. MCP-1 is induced by receptor activator of nuclear factor-ÎB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005; 280: 16163-9.
10. Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA,. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFÎB ligand for bone resorption. J Biol Chem 2006; 281: 1274-85.
11. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2387-92.
12. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008; 58: 1931-9.
13. Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem Biophys Res Commun 2010; 391: 1080-6.
14. Quinones MP, Ahuja SK, Jimenez F, Schaefer J, Garavito E, Rao A, et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest 2004; 113: 856-66.
15. + T cells. J Immunol 2004; 172: 890-8.
16. Dinarello CA,. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
17. Dinarello CA,. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-65.
18. Arend WP, Malyak M, Guthridge CJ, Gabay C,. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55.
19. Guo C, Dower SK, Holowka D, Baird B,. Fluorescence resonance energy transfer reveals interleukin (IL)-1-dependent aggregation of IL-1 type I receptors that correlates with receptor activation. J Biol Chem 1995; 270: 27562-8.
20. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP,. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-6.
21. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
22. Tolusso B, Pietrapertosa D, Morelli A, De Santis M, Gremese E, Farina G, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006; 7: 683-95.
23. Carreira PE, Gonzalez-Crespo MR, Ciruelo E, Pablos JL, Santiago B, Gomez-Camara A, et al. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. Arthritis Rheum 2005; 52: 3015-9.
24. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
25. Fujikado N, Saijo S, Iwakura Y,. Identification of arthritis-related gene clusters by microarray analysis of two independent mouse models for rheumatoid arthritis. Arthritis Res Ther 2006; 8: R100.
26. Iizasa H, Yoneyama H, Mukaida N, Katakoka Y, Naito M, Yoshida N, et al. Exacerbation of granuloma formation in IL-1 receptor antagonist-deficient mice with impaired dendritic cell maturation associated with Th2 cytokine production. J Immunol 2005; 174: 3273-80.
27. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, et al. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A 1997; 94: 12053-8.
28. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP,. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-8.
29. Sonoda Y, Mukaida N, Wang JB, Shimada-Hiratsuka M, Naito M, Kasahara T, et al. Physiologic regulation of postovulatory neutrophil migration into vagina in mice by a C-X-C chemokine(s). J Immunol 1998; 160: 6159-65.
30. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1814-27.
31. Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 2009; 68: 279-82.
32. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-7.
33. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009; 69: 7884-92.
34. Furuichi K, Kaneko S, Wada T,. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009; 13: 9-14.
35. Soehnlein O, Lindbom L, Weber C,. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood 2009; 114: 4613-23.
36. Schett G,. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009; 11: 210.
37. Serbina NV, Pamer EG,. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006; 7: 311-7.
38. Asagiri M, Takayanagi H,. The molecular understanding of osteoclast differentiation. Bone 2007; 40: 251-64.
39. Choi SJ, Han JH, Roodman GD,. ADAM8: a novel osteoclast stimulating factor. J Bone Miner Res 2001; 16: 814-22.
40. Ainola M, Li TF, Mandelin J, Hukkanen M, Choi SJ, Salo J, et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction. Ann Rheum Dis 2009; 68: 427-34.
41. McQueen FM, Ostendorf B,. What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther 2006; 8: 222.
42. Montgomery RR, Booth CJ, Wang X, Blaho VA, Malawista SE, Brown CR,. Recruitment of macrophages and polymorphonuclear leukocytes in Lyme carditis. Infect Immun 2007; 75: 613-20.
43. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111: 5457-66.
44. Sakurai A, Okahashi N, Nakagawa I, Kawabata S, Amano A, Ooshima T, et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-ÎB ligand. Infect Immun 2003; 71: 6019-26. (Pubitemid 37205655)
45. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA,. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther 2007; 9: R25.
46. Chakravarti A, Raquil MA, Tessier P, Poubelle PE,. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood 2009; 114: 1633-44.
47. Pillinger MH, Abramson SB,. The neutrophil in rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21: 691-714.
48. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S,. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 1997; 41: 56-62.
49. Gomez-Gaviro M, Dominguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007; 178: 8053-63.
50. Amano H, Morimoto K, Senba M, Wang H, Ishida Y, Kumatori A, et al. Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. J Immunol 2004; 172: 398-409.